Exiting quarter and strong demand going forward
STOCKHOLM – April 21, 2022 – ContextVision, a medical technology software company specializing in image processing and image analysis, today reports its first quarter results for 2022.
The quarter saw a very strong progress with a revenue of 27,2MSEK (20,3) and an EBITDA of 9,2MSEK (9,8).
“It has been an exciting quarter where we have been able to establish the new organization and fully focus on Medical Imaging business. During the quarter we signed both new customers as well as extended several current customers to include our state-of-the-art products Altumira and Rivent” – Ola Lindblad, acting CEO of ContextVision.
“We see strong demand”
Because of an increased demand from the overall market, we have released two new ultrasound products to extend the Rivent product family. A new 3D solution and a mobile solution aimed at the fast-growing handheld market. The feedback so far from the market has been very positive.
“With the shift in focus, the strong financials and the solid customer base we are off to a great start. We see strong demand going forward and we are looking forward to the rest of the year” – says Lindblad.
“Will give us a boost”
As of February 2022, the de-merger of Infiy Laboratories was finalized, which enables ContextVision to fully focus on the Company’s core business, a world leading medical imaging technology.
“Being able to focus 100 percent on our core business will give us a boost. I already see the results in this first quarter” – says Lindblad.
For further information, please contact ContextVision’s acting CEO, Ola Lindblad, at +46 8 750 35 50 or ola.lindblad@contextvision.se or visit www.contextvision.com.
About ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world.
Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act